Up 200% in 6 months, guess which ASX All Ords stock just hit another all-time high

This All Ords stock has made its investors very rich in recent months…

| More on:
Lab worker puts hands in the air and dances around

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One ASX All Ordinaries Index (ASX: XAO) stock has returned more than 200% to its investors over the past six months alone. Today, it celebrated a second feat by hitting another new all-time high.

Which ASX All Ords company? That would be Clarity Pharmaceuticals Ltd (ASX: CU6). Yes, it was only in early November last year that Clarity shares were trading at $1.06 each. Today, those same shares will set an investor back $3.27.

As mentioned, this Thursday also saw Clarity hit a new record high. Just after the market opened this morning, the All Ords pharmaceutical stock hit $3.31, its new all-time record.

Why has this ASX All Ords stock just hit a new record high?

Here at the Motley Fool, we've been tracking Clarity's rising star over most of the year. Back in January, my Fool colleague analysed Frazis Capital portfolio manager Michael Frazis's view on the company.

Frazis presciently called Clarity "the most exciting company I've come across in Australia lately", thanks to the favourable data surrounding its copper therapy treatment for late-stage prostate cancer.

Frazis also argued that the company remained vastly undervalued compared to its potential:

If their data continues to hold, this is still early days, and it remains a fraction of the value of recent acquisitions in the space with early stage data.

In March, we also discussed ASX broker Bell Potter's optimistic view on Clarity Pharmaceuticals. Bell Potter posited similar sentiments to Frazis, noting Clarity's prostate cancer patient's having "apparently with no disease progression, many months after commencing treatment".

At the time, Bell Potter gave the All Ords stock a 'speculative buy' rating alongside a share price target of $3.25. That target has certainly aged well.

It was only earlier this week that Clarity revealed its first patient to be dosed with two cycles of its treatment achieved "a complete response", with "undetectable levels of prostate specific antigen (PSA) for almost 6 months".

Much of Clarity's share price gains have come since this positive announcement. Since Monday this week, this ASX All Ords stock has gained a whopping 26.4%. Let's see where this exciting company is headed next.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Healthcare Shares

Why this ASX healthcare share is soaring 26% on study findings

This share is getting a lot of attention on Monday. What's happening?

Read more »

A woman stares at a computer with her face just inches from the screen.
Healthcare Shares

ASX IPO watch: Aspiring healthcare stock has attracted former Macquarie CEO to invest

And former federal health minister Greg Hunt is a board director.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 180% in a year, is it too late to buy Pro Medicus shares?

The question lingers.

Read more »

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

Pro Medicus share price rockets 13% on biggest ever contract win

Pro Medicus shares are leaping higher on Thursday.

Read more »

A woman with bright yellow hair wearing a brightly patterned blouse reacts to big news that she's reading on her phone.
Earnings Results

Guess which ASX 100 share is sinking despite record results

This healthcare stock had a record half. Here's what drove its growth.

Read more »

A group of men in the office celebrate after winning big.
Healthcare Shares

Is the CSL share price heading to $345? This analyst thinks so

Let's see why one analysts is tipping this high-quality stock to outperform.

Read more »

A young office worker is surrounded by peers who are clapping and congratulating her.
Healthcare Shares

Up 140% in 2024, here's why this ASX 200 healthcare stock is making news again today

It’s yet another positive update for this stock.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 ASX healthcare shares surging on big news

The ASX healthcare sector is higher on Tuesday and these stocks are among the strongest performers.

Read more »